Tyra Biosciences, Inc. (TYRA) stock
Close on Nov 11, 2026Market cap $1.25BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.25B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.81
- Dividend yield
- –
- Free cash flow yield
- -9.57%
Fundamentals
- Net income
- -$169.82M
- EPS, diluted
- -$2.64
- Free cash flow
- -$119.78M
- Book value per share
- $10.03
- Diluted shares
- 69M
Trading
- Next earnings
- Mar 1, 2027 (estimated, during market hours)
- Previous close
- $21.00
- Open
- $20.98
- Day's range
- $20.72 – $21.39
- Volume
- 532,708
- Average volume (20 days)
- 619,430
- Index membership
- Russell 2000 (since Dec 2021), Russell 3000 (since Feb 2022)
- Beta (5 years)
- 1.84
- 52-week range
- $13.83 – $40.65
- RSI (14 days)
- 47.9
- Volatility (1 year)
- 67.7%
- Relative volume
- 0.68×
- WACC
- 14.1%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TYRA | S&P 500 | Difference | TYRA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +5.2% | -2.4% | +7.6 pts | ||
| 3 months | -16.7% | -1.2% | −15.6 pts | ||
| Year to date | -20.2% | +12.3% | −32.5 pts | ||
| 1 year | +38.6% | +12.4% | +26.2 pts | ||
| 3 years | +78.3% | +78.8% | −0.5 pts | +21.3% | +21.4% |
| 5 years | -25.7% | +75.2% | −100.9 pts | -5.8% | +11.9% |
| 10 years | +69800.0% | +311.1% | +69488.9 pts | +92.5% | +15.2% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Tyra Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNews
- Results
- Results
- Results
- Results
About Tyra Biosciences
Pharmaceutical Preparations
Tyra Biosciences, Inc. is a clinical-stage biotechnology company developing targeted small molecule therapies focused on Fibroblast Growth Factor Receptor (FGFR) biology. The company utilizes its proprietary SNÅP drug design platform, combining protein crystallography, cell-based assays, and animal models to discover therapies for oncology and rare genetically defined conditions. Its product pipeline includes oral dabogratinib, an FGFR3-selective candidate evaluated for low-grade upper tract urothelial carcinoma, intermediate-risk non-muscle invasive bladder cancer, and achondroplasia. Other pipeline candidates include TYRA-430 for FGF19-positive hepatocellular carcinoma and TYRA-200 for FGFR2-altered intrahepatic cholangiocarcinoma.
Company profile, executives and historyTyra Biosciences stock: common questions
What is Tyra Biosciences's stock price?
TYRA closed at $20.97 on Nov 11, 2026, down 0.14% on the day. Over the past 52 weeks it traded between $13.83 and $40.65.
What is Tyra Biosciences's market cap?
Tyra Biosciences was worth $1.25B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TYRA's P/E ratio?
Tyra Biosciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.64), so it has no meaningful P/E ratio.
Does Tyra Biosciences pay a dividend?
No. Tyra Biosciences has not paid a cash dividend over the last twelve months.
When does Tyra Biosciences report earnings next?
Tyra Biosciences is expected to report Q4 FY2026 results on Mar 1, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has TYRA stock performed over the past year?
Including dividends, TYRA returned +38.6% over the past year, against +12.4% for the S&P 500.
How many TYRA shares are sold short?
10M shares were sold short at the latest FINRA report, 36.28% of the float, or 15.3 days of average trading volume.
Who are Tyra Biosciences's competitors?
Companies most similar to Tyra Biosciences by business, industry and size include BOLD, IDYA, PRLD, BBOT, ERAS.
See a number that looks wrong?